曲妥珠单抗联合奥沙利铂、卡培他滨治疗人类表皮因子受体-2阳性晚期胃癌的近期疗效观察  

Observation on Trastuzumab Combined with Oxaliplatin and Capecitabine in Treating Advanced Gastric Cancer with positive human epidermal factor receptor

作　　者：曹博威 张文斌[1] Cao Bowei;Zhang Wenbin(Department of Gastrointestinal(Oncology)Surgery,The First Affiliated Hospital of Xinjiang Medical University,830054,Urumqi,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]新疆医科大学第一附属医院胃肠(肿瘤)外科,新疆维吾尔自治区乌鲁木齐830054

出　　处：《中外医药研究》2023年第18期6-8,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

基　　金：新疆维吾尔自治区自然科学基金资助项目(编号:2022D01D77)。

摘　　要：目的:观察曲妥珠单抗联合奥沙利铂+卡培他滨(XELOX)方案治疗人类表皮因子受体-2(HER-2)阳性晚期胃癌的近期疗效。方法:选取2020年4月—2022年4月新疆医科大学第一附属医院胃肠(肿瘤)外科收治的HER-2阳性晚期胃癌患者98例为观察对象,按随机数字表法分为对照组与观察组,各49例。对照组给予XELOX方案治疗,观察组给予曲妥珠单抗联合XELOX方案治疗。比较两组患者血清肿瘤标志物水平、疾病控制情况、不良反应发生情况及近期生存情况。结果:治疗后,两组患者胃癌相关抗原、癌胚抗原、糖类抗原19-9水平均较治疗前下降,观察组低于对照组,差异有统计学意义(P<0.001);观察组疾病控制率、客观缓解率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组中位生存期长于对照组,差异有统计学意义(P<0.001)。结论:曲妥珠单抗联合XELOX方案治疗HER-2阳性晚期胃癌的近期疗效显著,能明显降低血清肿瘤标志物水平,不会增加不良反应,延长中位生存期。Objective:To observe the recent therapeutic effect of trastuzumab combined witoxaliplatin and capecitabine(XELOX)in the treatment advanced gastric cancer with positive human epidermal factor receptor-2(HER-2).Methods:98 patients with HER-2-positive advanced gastric cancer admitted to the Department of Gastrointestinal(Oncology)Surgery of the First Affiliated Hospital of Xinjiang Medical University from April 2020 to April 2022 were selected as the observation subjects,and were divided into the control group and the observation group according to the method of randomized numerical table,with 49 cases each.The control group was treated with XELOX schema,and the observation group was treated with trastuzumab combined with XELOX.Serum tumor marker levels,disease process,occurrence of adverse reactions and recent survival rate were compared between the two groups.Results:After treatment the following indexes of two groups decreased compared with those before treatment:serum gastric cancer relevant antigen,carcinoembryonic antigen and serum carbohydrate antigen 19-9;and those indexes of observation group was lower than those of the control group with a statistically significant difference(P<0.001);the disease control rate and the objective relief rate of the observation group were higher than those of the control group with a significant difference(P<0.05);the incidence rates of adverse reactions of the two groups were compared with one another,and there was no statistical significance in the difference(P>0.05);the median survival of the observation group was longer than that of the control group,and the difference was statistically significant(P<0.001).Conclusion:The recent efficacy of trastuzumab combined with XELOX schema in the treatment of HER-2-positive advanced gastric cancer is remarkable,which can significantly reduce the serum tumor marker levels,does not increase the adverse effects and prolongs the median survival.

关 键 词：曲妥珠单抗 奥沙利铂 卡培他滨 人类表皮因子受体-2阳性 晚期胃癌 

分 类 号：R73[医药卫生—肿瘤]